Results 131 to 140 of about 20,950 (257)

Psoriasis and comorbid diseases: Implications for management. [PDF]

, 2017
: As summarized in the first article in this continuing medical education series, the currently available epidemiologic data suggest that psoriasis may be a risk factor for cardiometabolic disease.
Gelfand, JM, Grewal, S, Langan, SM, Mehta, NN, Ogdie, A, Takeshita, J, Van Voorhees, AS   +6 more
core   +1 more source

A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis

Journal of dermatological treatment (Print)
Aim: Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare. Methods: We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.
Guanghan Wang, Xiaojing Hu, Shixin Han, Meijuan Zhou   +3 more
semanticscholar   +1 more source

Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals [PDF]

, 2017
Background: Inflammatory back pain (IBP) is an early feature of ankylosing spondylitis (AS) and its detection offers the prospect of early diagnosis of AS. However, since back pain is very common but only a very small minority of back pain sufferers have
Abraham, Ajay M., Alberts, Alan R., Alper, Jeffrey A., Anisfeld, Andrew M., Aptowitzer, Tanya, Baeten, Dominique, Baeten, Dominique, Baraliakos, Xenofon, Barrick, Thomas R., Barry, A., Belkhiri, Abdelghani, Bertolino, Arthur, Beutler, Anna, Birrell, Fraser, Braun, Jurgen, Braun, Jurgen, Carr, Andrew, Cavill, Charlotte, Chattopadhyay, Chandrabhusan, Conaghan, Philip G., Cooper, Cyrus, Cooper, Philip, Costa, Luisa, de Vries, Corinne, Deakin, Greg, Devenport, Jenny, DiCarlo, Julie, Downham, Christina, Emery, Paul, Emery, Paul, Fedkov, Dmytro, Flurey, Caroline A., Francis, Roger M., Gadola, Stephan, Gaffney, Karl, Gimpel, Mo, Gladman, Dafna, Godtschailk, Malcolm, Goldstein, Neil, Gordon, Caroline, Griffith, Nina, Gsteiger, Sandro, Guile, Geoffrey, Hamilton, Louise, Harris, Claire, Hermansson, Monika, Hewlett, Sarah, Howard, Matthew, Howe, Franklyn A., Hueber, Wolfgang, Hueber, Wolfgang, Hughes, Rod, Iaremenko, Oleg, Jadon, Deepak, Jameson, Karen, Jones, Gareth T., Kalunian, K., Kavanaugh, Arthur, Keat, Andrew, Kellner, Herbert, Kellner, Herbert, Kiely, Patrick, Kilgallen, B., Korendowych, Eleanor, Krueger, Gerald, Landewe, R., Landewe, R., Laurent, Didier D., MacDonald, Alan G., Macfarlane, Gary J., Macgregor, Alex, Macleod, Iain, Mann, Kay D., McHugh, Neil, McInnes, Iain, McInnes, Iain, McInnes, Iain, Mease, Philip, Morris, Marianne, Morton, Linda, Newman, David, Ng, Wan-Fai, Olech, Ewa, Paramarta, I., Pearce, Mark S., Peterfy, Charles G., Petri, M., Pollock, Jon, Remedios, Denis, Richards, Pam, Sanyal, Kaushik, Sieper, Joachim, Sieper, Joachim, Smee, Cori, Sofat, Nidhi, Stokes, Maria, Strand, V., Tillett, William, Toms, Andoni, Troum, Orrin M., van der Heijde, D., van der Heijde, D., van der Heijde, Desiree, Van Laar, Jaap, Van Laar, Jaap, Wajed, Julekha, Waldron, Nicola, Wallace, D., Wallis, Dinny, Wollenhaupt, Jurgen, Wollenhaupt, Jürgen, Wordsworth, Bryan P., Wordsworth, Bryan P., Wright, Andrew M., Wright, Andrew M., Xu, Weichun   +115 more
core  

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs : a systematic review and economic evaluation [PDF]

, 2017
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (
Adams, Adams, Ali, Anon, Antoni, Antoni, Antoni, Arthritis Foundation, Asaria, Askling, Atteno, Bansback, Baranauskaite, Bird, Bojke, Bowcock, Briggs, Brodszky, Capogrosso-Sansone, Carmona, Cawson, Centre for Reviews and Dissemination, Chang, Chen, Coates, Codreanu, Corbett, Corbett, Corbett, Craig, Cummins, Curtis, Department of Health (DH), Dias, Dias, Dias, Dixon, Dolan, Drummond, Eder, Einarson, Emery, European Medicines Agency, Fagerli, Fagerli, Fagerli, Felson, Galadari, Genovese, Girolomoni, Gladman, Gladman, Gladman, Glintborg, Glintborg, Glintborg, Gossec, Gottlieb, Gottlieb, Gottlieb, Gottlieb, GRAPPA, Gratacós, Haberhauer, Hartman, Helliwell, HM Treasury, Husted, Iannone, Joint Formulary Committee, Joint Formulary Committee, Julious, Kane, Karlsson, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kobelt, Kristensen, Krueger, Kyle, Langley, Lefebvre, Lefebvre, Leung, Leung, Madan, Maneiro, Mariette, McInnes, McInnes, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Michelsen, Migliore, Moll, Morgan, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence (NICE), Novartis Pharmaceuticals, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, O’Connor, Picchianti-Diamanti, Poole, Poyner, Ramiro, Reveille, Ritchlin, Ritchlin, Rodgers, Ruderman, Saad, Saad, Salisbury NHS Foundation Trust, Schett, Shiel, Simard, Singh, Smith, Spiegelhalter, Sterry, Stolfa, Tarp, Taylor, Thaçi, Torii, Torre Alonso, Tzanetakos, Ungprasert, Wang, Wong, Wong, Yang, Yang, Yang, Zisman   +157 more
core   +2 more sources

Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study

Journal of Personalized Medicine
Background: the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis ...
N. Bernardini, A. Dattola, Raimondo Rossi, G. Pagnanelli, P. Amerio, L. Atzori, C. Mugheddu, Viviana Lora, Domenico Giordano, Lucia Finistauri Guacci, S. Persechino, A. Richetta, N. Skroza, C. Potenza   +13 more
semanticscholar   +1 more source

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Arthritis Research & Therapy, 2019
BackgroundSecukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ...
A. Deodhar, P. Mease, I. McInnes, X. Baraliakos, K. Reich, A. Blauvelt, C. Leonardi, B. Porter, A. D. Gupta, A. Widmer, L. Pricop, T. Fox   +11 more
semanticscholar   +1 more source

NCR+ ILC3 maintain larger STAT4 reservoir via T-BET to regulate type 1 features upon IL-23 stimulation in mice [PDF]

, 2018
Innate lymphoid cells (ILCs) producing IL-22 and/or IL-17, designated as ILC3, comprise a heterogeneous subset of cells involved in regulation of gut barrier homeostasis and inflammation.
Kanno, Yuka, Mikami, Yohei, O'Shea, John J, Santoni, Angela, SCARNO, GIANLUCA, Sciumè, Giuseppe, Shih, Han-Yu, Zitti, Beatrice   +7 more
core   +1 more source

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry

Archives of Dermatological Research
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis.
K. Papp, M. Gooderham, C. Lynde, Danielle Brassard, Faisal Al-Mohammedi, V. Prajapati, I. Delorme, L. Albrecht, Richard Haydey, M. Alam, J. Beecker, Sanjay Siddha, Marie Maguin, Mahmoud S Farag, Antonio Vieira, L. Řiháková, R. Langley   +16 more
semanticscholar   +1 more source

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Data from 2731 patients with hidradenitis suppurativa (HS) treated with biologics for 12–16 weeks in phase III randomized controlled trials (RCT) were included in a network meta‐analysis (NMA). Adalimumab showed the highest efficacy in achieving a clinical HS response 50 (HiSCR50) and the lowest incidence of adverse events (AE).
Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, Lars E. French, Benjamin Kendziora   +4 more
wiley   +1 more source

Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease

European Journal of Medical Research
Background Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful ...
Ronghui Li, Haibo Lei, Chunjiang Wang, Xiang Liu   +3 more
doaj   +1 more source